Benitec Biopharma Ltd Company Profile (NASDAQ:BNTC)

About Benitec Biopharma Ltd (NASDAQ:BNTC)

Benitec Biopharma Ltd logoBenitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic. It is focused on commercialization by licensing and partnering of patents and licenses in biotechnology, in functional genomics, with applications in biomedical research and human therapeutics. It has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, deoxyribonucleic acid (DNA)-directed ribonucleic acid interference (ddRNAi). The Company is engaged in developing treatments for chronic human conditions, such as hepatitis B, wet age-related macular degeneration (AMD), and oculopharyngeal muscular dystrophy (OPMD) based on this technology.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BNTC
  • CUSIP: N/A
  • Web: www.benitec.com
Capitalization:
  • Market Cap: $20.22 million
  • Outstanding Shares: 8,791,000
Average Prices:
  • 50 Day Moving Avg: $2.60
  • 200 Day Moving Avg: $2.23
  • 52 Week Range: $1.20 - $5.48
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.58
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $7.22 million
  • Price / Sales: 2.80
  • Book Value: $1.58 per share
  • Price / Book: 1.46
Profitability:
  • EBIDTA: ($6,880,000.00)
Debt:
  • Current Ratio: 21.89%
  • Quick Ratio: 21.89%
Misc:
  • Average Volume: 409,823 shs.
  • Beta: 2.53
  • Short Ratio: 0.51
 

Frequently Asked Questions for Benitec Biopharma Ltd (NASDAQ:BNTC)

What is Benitec Biopharma Ltd's stock symbol?

Benitec Biopharma Ltd trades on the NASDAQ under the ticker symbol "BNTC."

Who are some of Benitec Biopharma Ltd's key competitors?

When did Benitec Biopharma Ltd IPO?

(BNTC) raised $0 in an IPO on Thursday, August 6th 2015. The company issued 0 shares at $0.00 per share. BMO Capital Markets and Maxim Group LLC served as the underwriters for the IPO and Roth Capital Partners was co-manager.

How do I buy Benitec Biopharma Ltd stock?

Shares of Benitec Biopharma Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Benitec Biopharma Ltd stock cost?

One share of Benitec Biopharma Ltd stock can currently be purchased for approximately $2.30.

Analyst Ratings

Consensus Ratings for Benitec Biopharma Ltd (NASDAQ:BNTC) (?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A

Analysts' Ratings History for Benitec Biopharma Ltd (NASDAQ:BNTC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/3/2017Maxim GroupReiterated RatingHoldN/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Benitec Biopharma Ltd (NASDAQ:BNTC)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Benitec Biopharma Ltd (NASDAQ:BNTC)
Current Year EPS Consensus Estimate: $-0.10 EPS
Next Year EPS Consensus Estimate: $-0.24 EPS

Dividends

Dividend History for Benitec Biopharma Ltd (NASDAQ:BNTC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Benitec Biopharma Ltd (NASDAQ:BNTC)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Benitec Biopharma Ltd (NASDAQ:BNTC)
Latest Headlines for Benitec Biopharma Ltd (NASDAQ:BNTC)
Source:
DateHeadline
finance.yahoo.com logoKey pre-clinical data on oculopharyngeal muscular dystrophy (OPMD) published in Nature Communications
finance.yahoo.com - April 7 at 8:35 AM
finance.yahoo.com logoHere's Why Benitec Biopharma Stock Soared 79.7% Higher This Morning
finance.yahoo.com - April 7 at 8:35 AM
finance.yahoo.com logoRising Biotechs: Paratek Among Stocks Surging On Trial Results
finance.yahoo.com - April 7 at 8:35 AM
finance.yahoo.com logoToday's Research Reports on Biotech Stocks to Watch: Benitec Biopharma and Paratek Pharmaceuticals
finance.yahoo.com - April 7 at 8:35 AM
finance.yahoo.com logoIncreased Volume Spurs Stock Prices of Benitec Biopharma, Regulus Therapeutics
finance.yahoo.com - March 27 at 11:49 AM
finance.yahoo.com logoBenitec Biopharma completes second tranche placement to Nant Capital to raise A$5.45 million
finance.yahoo.com - March 13 at 11:50 AM
finance.yahoo.com logoBenitec Biopharma to present expanded data set from pivotal data in hepatitis B virus (HBV) in vivo model at International Liver Meeting in Shanghai, China
finance.yahoo.com - February 16 at 8:49 AM
finance.yahoo.com logoM&A Activity Could Kick Start Biotech Industry's Recovery in 2017: Today's Report on Benitec and Protalix
finance.yahoo.com - February 3 at 4:09 PM
benzinga.com logoMid-Day Market Update: Shutterfly Drops On Downbeat Earnings; Mead Johnson Shares Spike Higher
www.benzinga.com - February 2 at 9:14 PM
nasdaq.com logoMid-Afternoon Market Update: Weatherford Rises Following Q4 Results; Ralph Lauren Shares Plunge
www.nasdaq.com - February 2 at 4:09 PM
finance.yahoo.com logoBenitec Biopharma makes significant progress in ocular program
finance.yahoo.com - February 2 at 4:09 PM
streetinsider.com logoBenitec Biopharma (BNTC) Gains After Announces Progress on ddRNAi Technology
www.streetinsider.com - February 2 at 4:09 PM
finance.yahoo.com logoWhy Benitec More Than Doubled
finance.yahoo.com - February 2 at 4:09 PM
finance.yahoo.com logoBenitec initiates development work on head and neck cancer programs after executing Collaboration Agreement with Nant Capital
finance.yahoo.com - January 30 at 3:52 PM
247wallst.com logoTuesday’s Top Biopharma Movers
247wallst.com - January 19 at 5:03 PM
rttnews.com logoBenitec Biopharma (BNTC) Leaped After European Orphan Drug Designation
www.rttnews.com - January 19 at 5:03 PM
benzinga.com logoBenitec Receives Orphan Drug Designation in the...
www.benzinga.com - January 18 at 3:24 PM
streetinsider.com logoBenitec Biopharma (BNTC) BB-301 Granted Orphan Drug Designation in EU
www.streetinsider.com - January 18 at 3:24 PM
finance.yahoo.com logoBlog Coverage Benitec Biopharma Secures Orphan Drug Designation for its Product Treating Patients with Oculopharyngeal Muscular Dystrophy
finance.yahoo.com - January 18 at 3:24 PM
finance.yahoo.com logoBenitec Stock Up on Orphan Drug Status for BB-301 in EU
finance.yahoo.com - January 18 at 3:24 PM
finance.yahoo.com logoBiotech Industry Outperforming Markets in 2017: Latest Reports on Benitec Biopharma and Tandem Diabetes Care
finance.yahoo.com - January 18 at 3:24 PM
us.rd.yahoo.com logoBenitec Receives Orphan Drug Designation in the European Union for BB-301, a ddRNAi Therapeutic in Development for the Treatment of Oculopharyngeal Muscular Dystrophy
us.rd.yahoo.com - January 17 at 9:32 AM
us.rd.yahoo.com logoBenitec in-licenses clinical program for head and neck cancer from NantWorks
us.rd.yahoo.com - December 23 at 4:07 PM
us.rd.yahoo.com logo7:13 am Benitec Biopharma in-licenses clinical program for head and neck cancer from NantWorks; financial terms not disclosed
us.rd.yahoo.com - December 23 at 4:07 PM
finance.yahoo.com logoBenitec releases pivotal data in an in vivo hepatitis B model
finance.yahoo.com - December 20 at 8:00 AM
finance.yahoo.com logo7:38 am Benitec Biopharma announced significant progress on use of the company's technology for development of a ddRNAi based therapeutic for the treatment of hepatitis B virus
finance.yahoo.com - December 20 at 8:00 AM

Social

Chart

Benitec Biopharma Ltd (BNTC) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff